On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial.

or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least ...